Yang Jiarui, Liu Yushi, Xu Yanhui, Li Xiaodan, Fu Jiayu, Jiang Xiaodan, Chou Yilin, Ma Jiahui, Hao Ran, Zhang Rong, Qiu Weiqiang, Li Xuemin
Department of Ophthalmology, Peking University Third Hospital, Beijing, People's Republic of China.
Department of Neurobiology, Health Science Center, School of Basic Medical Sciences, Peking University, Beijing, People's Republic of China.
Drug Des Devel Ther. 2019 Jul 18;13:2381-2391. doi: 10.2147/DDDT.S203464. eCollection 2019.
To present a new ocular nebulization therapy for the treatment of dry eye disease (DED) and investigate the efficacy of vitamin B12 (VB12) and oxytocin (OXT) nebulization with clinical parameters and in vivo confocal microscopy (IVCM). Thirty-eight patients with DED were enrolled, with 19 receiving VB12 nebulization and 19 receiving OXT nebulization twice weekly for 3 months. Clinical signs and symptoms including Ocular Surface Disease Index, self-assessment of light sensitivity and dryness, tear meniscus height, tear break-up time (BUT), and corneal staining, along with IVCM data of basal epithelial cell density, sub-basal dendritic cell (DC) density, nerve density, and nerve tortuosity were acquired at baseline, 1 month, and 3 months after starting treatment. Patients treated with VB12 improved significantly in all signs and symptoms except for nerve tortuosity during the three-month treatment, while OXT demonstrated similar effects apart from BUT and nerve tortuosity. VB12 group revealed a higher BUT at 1 month and 3 months with a higher basal epithelial cell density at 3 months compared with OXT group, and a lower DC density was observed in OXT group at 1 month. Change of basal epithelial cell density was more significant at 3 months in VB12 group, with OXT group showing a significantly higher DC reduction at 1 month. The nebulization therapy delivering VB12 and OXT appears to be effective in improving the symptoms and signs of dry eye, with a relatively stronger effect of BUT elevation and epithelial repair in VB12 and anti-inflammation in OXT nebulization.
介绍一种用于治疗干眼症（DED）的新型眼部雾化疗法，并通过临床参数和体内共聚焦显微镜（IVCM）研究维生素B12（VB12）和催产素（OXT）雾化的疗效。招募了38例DED患者，其中19例接受VB12雾化，19例接受OXT雾化，每周两次，共3个月。在开始治疗的基线、1个月和3个月时，获取包括眼表疾病指数、对光敏感度和干燥程度的自我评估、泪膜高度、泪膜破裂时间（BUT）和角膜染色等临床体征和症状，以及基底上皮细胞密度、基底膜下树突状细胞（DC）密度、神经密度和神经弯曲度的IVCM数据。接受VB12治疗的患者在三个月的治疗期间，除神经弯曲度外，所有体征和症状均有显著改善，而OXT除BUT和神经弯曲度外也表现出类似效果。与OXT组相比，VB12组在1个月和3个月时BUT更高，在3个月时基底上皮细胞密度更高，且在1个月时OXT组的DC密度更低。VB12组在3个月时基底上皮细胞密度变化更显著，OXT组在1个月时DC减少更显著。给予VB12和OXT的雾化疗法似乎对改善干眼的症状和体征有效，VB12在提高BUT和上皮修复方面效果相对较强，OXT雾化在抗炎方面效果相对较强。
